Press Releases
August 17, 2010 Cornerstone Pharmaceuticals Appoints Dr. Dorit Arad Director of Research and Development for its Israeli Operations
August 05, 2010 Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First-in-Class Anti-Cancer Agent CPI-613
June 07, 2010 Cornerstone Pharmaceuticals Appoints Timothy Sullivan Executive Vice President and Head of Corporate Development
April 19, 2010 Cornerstone Pharmaceuticals Partners with Wake Forest University on Clinical Trial of CP-613 for Hematologic Malignancies
March 22, 2010 Cornerstone Pharmaceuticals Enters Into a Collaboration Agreement with the U.S. National Cancer Institute
February 08, 2010 Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First- In-Class Anti-Cancer Agent CPI-613
November 11, 2009 Cornerstone Pharmaceuticals Chosen Among Top 10 Most Interesting Oncology Projects
November 04, 2009 Leading Oncologist Dr. Robert Shepard Joins Cornerstone Pharmaceuticals as Acting Chief Medical Officer
